TuesdayMay 11, 2021 11:29 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Announces Sales Team Expansion

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced the hiring of four additional sales representatives, including three for the veterinary market and one for the contract drug manufacturing market. “We are excited to have recruited very talented and experienced sales representatives from some of the biggest names in veterinary health care,” said Dr. Jack Regan, LexaGene’s CEO and founder. “Our new sales representatives have universally expressed optimism about selling LexaGene’s technology into veterinary hospitals, and the same is true for our sales representative targeting contract drug manufacturing organizations.…

Continue Reading

WednesdayApr 14, 2021 10:53 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Host Private Seminar to Present MiQLab Data from Recent Study

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced that it will host a private event featuring Dr. Shelley Rankin, a professor of microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). Attended by a select group of veterinarians, the private seminar will feature data compiled by Rankin based on her studies evaluating the use of LexaGene’s MiQLab to detect Staphylococcus in specimens gathered from canine skin infections. The event will also include information regarding the use of molecular diagnostics in veterinary medicine as well as analytical and…

Continue Reading

ThursdayApr 01, 2021 10:31 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Reports Update in Shareholder Letter

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has provided a corporate update in a shareholder letter from LexaGene CEO and founder Dr. Jack Regan. In the letter, Regan reported that the company had crossed a major milestone by securing a sales contract in both the drug and vaccine manufacturing market and in the veterinary medicine space; both sales were the result of successful technology demonstrations, the letter noted. The company has also focused on ensuring consistency in microfluidic operations across MiQLab(TM) systems, Regan observed, noting that expectations have now been…

Continue Reading

TuesdayMar 02, 2021 11:15 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Secures $3.6M from Exercised Warrants

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced its receipt of approximately CA$3.6M (US$2.9M) in warrant exercises since the start of 2021. “Achieving our first commercial sales in combination with a very positive outlook for 2021 has resulted in the appreciation of our share price over the last few months,” said Dr. Jack Regan, LexaGene’s CEO and founder. “The receipt of exercised warrants has significantly added to our treasury and puts us in a strong financial position for 2021.” To view the full press release, visit https://ibn.fm/krb5U About…

Continue Reading

FridayFeb 12, 2021 11:45 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Announces Change in Management, New Board Appointment

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Daryl Rebeck will resign from the board and his position as the president of LexaGene effective Feb. 15, 2021. Stephen J. Mastrocola has joined the company’s board of directors and brings almost 40 years of accounting and auditing experience working with public and private companies. “I’m immensely grateful to Daryl for being my partner and helping me found this company four years ago. I would like to thank him for all his hard work and leadership and wish him…

Continue Reading

WednesdayFeb 10, 2021 12:37 pm

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Configures MiQLab(TM) to Detect Variants of COVID-19 Pathogen

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has successfully configured a MiQLab(TM) system to detect mutant sequences unique to the United Kingdom (“UK, B.1.1.7”) 1 and South African (“SA, B.1.351”) 2 variants of SARS-CoV-2, the pathogen that causes COVID-19.  “Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab,” said Dr. Jack Regan, LexaGene’s CEO and founder. “After just two full work days of having these reagents in-house,…

Continue Reading

WednesdayJan 13, 2021 11:24 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Initiates Program to Identify UK, South African COVID Sequences

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant 1 (aka SARS-CoV-2 VUI 202012/01),”…

Continue Reading

WednesdayJan 06, 2021 10:50 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Participation in Two Upcoming Virtual Events

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, will be presenting at two investor conferences in January: the SNN Network Canada Virtual Event and the H.C. Wainwright Bioconnect 2021 Virtual Conference. Company founder and CEO Dr. Jack Regan will represent LexaGene at both events. The SNN Network Canada Virtual Event is scheduled for Thursday, Jan. 7, 2021; LexaGene’s live presentation is slated to begin at 1:30 p.m. ET. Those interested can find the webcast presentation on the conference event platform under the agenda tab following the event. The H.C. Wainwright Bioconnect…

Continue Reading

WednesdayDec 30, 2020 10:51 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Commences FDA EUA Study for POC COVID-19 Testing

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has started a series of studies required by the FDA for Emergency Use Authorization (“EUA”) testing for its COVID-19 assay in a point-of-care (“POC”) environment using its fully automated MiQLab(TM) system. “I’m excited we have progressed to the point where we have started our FDA study. Our open-access technology is unlike any other on the market today, as it could be configured quickly to detect new variants, such as the recent UK variant 1 (aka SARS-CoV-2 VUI 202012/01),”…

Continue Reading

ThursdayDec 17, 2020 10:42 am

QualityStocksNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Proprietary Systems to be Utilized at Leading Specialty, Emergency Veterinary Care Hospitals

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has finalized agreements to place its exclusive MiQLab(TM) systems at two specialty and emergency veterinary hospitals as part of the company’s Early Access Program (“EAP”); the company anticipates placing the systems in early 2021. The two practices are Veterinary Specialty Hospital (“VSH”) of Palm Beach Gardens, Florida, and Denver Animal Emergency in Denver, North Carolina. According to the agreement, the two leading hospitals will evaluate MiQLab-generated data, which is generated quickly, against traditional culture and sensitivity testing, which can take up to five days…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered